(MENAFN- Evertise Digital) Soligenix Inc. (NASDAQ: SNGX) is pioneering a novel approach to combat the growing threat of antibiotic resistance with its SGX943 therapy. This innovative treatment is based on dusquetide, an Innate Defense Regulator (IDR) that modulates the body's immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections. This development is crucial as the medical community urgently seeks alternative treatments in the face of escalating antibiotic resistance.

The company's portfolio, which includes both specialized biotherapeutics and public health solutions, targets areas with significant unmet medical needs. Among its developments is HyBryte(TM) (SGX301), a novel photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL), and synthetic hypericin (SGX302) for psoriasis. Additionally, Soligenix is exploring the use of dusquetide (SGX942) for inflammatory diseases, including oral mucositis in head and neck cancer, and SGX945 in Behçet's disease.

Soligenix's Public Health Solutions business segment is also making strides with its vaccine programs, including RiVax(R) for ricin toxin, vaccines targeting filoviruses like Marburg and Ebola, and CiVax(TM) for COVID-19 prevention. These programs utilize the company's proprietary heat stabilization platform technology, ThermoVax(R), and have been supported by government grants and contracts from notable agencies such as the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).

The advancement of SGX943 and Soligenix's broader portfolio represents a significant step forward in addressing the global challenge of antibiotic resistance, offering hope for new treatments that can bypass the limitations of traditional antibiotics.

This news story relied on content distributed by None . Blockchain Registration, Verification & Enhancement provided by NewsRampTM. The source URL for this press release is Soligenix Inc. Advances Novel Immunotherapy to Combat Antibiotic Resistance.

MENAFN01072025005025011514ID1109748136